Services
What we do
Transforming complex science
into market access outcomes.
We work across the full market access and evidence lifecycle, from early asset strategy to reimbursement and launch. Six connected practice areas, led by senior experts, AI-enabled, and built around your asset and its markets.
Strategy & Market Access
Global and regional market access strategy, pricing and launch sequencing, competitive landscape, payer research, and due diligence. Includes international reference pricing (IRP) simulation and optimised launch sequencing to protect price corridors across markets.
- Global & regional market access strategy
- Pricing strategy & launch sequencing
- International reference pricing (IRP) simulation
- Competitive landscape & payer research
- Commercial due diligence
Health Economics & Evidence
Systematic literature reviews, cost-effectiveness and budget impact models, evidence generation plans, and real-world evidence strategy, built to withstand HTA scrutiny. Includes PICO alignment: predicting the population, intervention, comparator and outcomes that HTA bodies will require, ahead of submission.
- Systematic literature reviews & network meta-analyses
- Cost-effectiveness & budget impact models
- Evidence generation plans & RWE strategy
- PICO alignment ahead of submission
- Synthetic control arms for rare-disease indications
- Burden of illness studies
HTA & Reimbursement
HTA landscape assessments, submission strategy and dossier development, payer engagement and advisory boards, reimbursement negotiation support. We work across the regulatory–HTA "double gate", so data generated for FDA or EMA also meets payer value requirements, including the EU Joint Clinical Assessment (JCA).
- HTA landscape assessments & strategy
- Dossier development (NICE, CADTH, HAS, G-BA, AIFA, PBAC, JCA)
- Payer engagement & advisory boards
- Reimbursement negotiation support
- Regulatory–HTA evidence alignment ("double gate")
Value Communication
Global Value Dossiers, value proposition development, payer communication materials, and scientific publications strategy. Evidence packages that can be updated as new real-world data emerges, not static documents.
- Global Value Dossiers (GVDs) & payer materials
- Value proposition & messaging development
- Scientific publications strategy
- Dynamic value packages updated as RWE emerges
- Stakeholder-specific communication
Project & Delivery Management
End-to-end project management, cross-functional workshop facilitation, and training. On time, on scope, on budget. Every engagement runs against a defined plan with weekly review calls, structured interim reports, and immediate escalation of any scope, timeline, or quality risk.
- End-to-end project management
- Cross-functional workshop facilitation
- Capability training & team development
- Standard 8 / 12 / 16-week engagement structures
- Risk & issue management with audit trail
AI Enablement
AI solution development, AI strategy, operational execution and training. We embed capability across your teams so AI becomes part of how they work, not just a tool. We build specialist tools for the evidence and market access lifecycle, tested against published benchmarks before they touch client work, not generic AI applied to specialist problems.
- AI solution development & integration
- AI strategy definition & readiness assessment
- Operational execution & workflow embedding
- Team capability training
- Governance, audit trail, and compliance design
Where we work
Rare. Oncology. Cardiovascular. MedTech.
Deep expertise in the indications where market access is hardest, and in the markets where evidence and pricing decisions are made.
Rare & ultra-rare disease
12+ indications including FOP, gMG, AML, PNH, aHUS, PKU, gPP. Synthetic control arms and burden of illness studies where traditional RCTs are not feasible.
Oncology
Solid tumours, haematological malignancies, targeted therapies, and emerging immuno-oncology assets across global markets.
Cardiovascular, CNS, autoimmune, infectious disease
Broad therapy area capability supported by our global advisor network and specialist clinical KOLs across each domain.
Medical technology
Robotic surgery, implantable devices, cardiac rhythm management, and haemodynamic monitoring - across pharma, biotech, and medtech sponsors.
Working on a market access challenge?
Every engagement begins with a direct conversation with the senior practitioner who will lead it.
Book a 30-minute call